Literature DB >> 3567369

In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.

M R Motta, M Baccarani, S Rizzi, R Fanin, G Fasola, C Poluzzi, S Tura.   

Abstract

Low dose Arabinosyl Cytosine (LD ARA-C) is widely used for treatment of acute non-lymphocytic leukemia (ANLL) and myelodysplastic syndrome (MDS) in the elderly, based on a favorable response rate and on the hypothesis that LD ARA-C can induce differentiation or maturation of leukemic cells. We investigated the effect of low concentration of ARA-C on the growth of marrow cells that were obtained from 6 cases of MDS and from 11 cases of ANLL by using the in vitro culture system for normal granulo-monocyte precursors (CFU-GM). At ARA-C concentrations equal to or higher than 1 ng/ml cell growth was inhibited in a dose-dependent manner. At ARA-C concentration of 0.1 ng/ml cell growth was slightly affected, but colony number and colony cell composition were identical to control cultures. This experiment did not support the hypothesis that ARA-C can induce leukemic cells to recover any normal growth patterns but confirmed that even very low ARA-C concentrations can inhibit or slow down leukemic cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567369     DOI: 10.1007/bf00320878

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  35 in total

Review 1.  The differentiation of myeloid leukaemia cells: new possibilities for therapy.

Authors:  L Sachs
Journal:  Br J Haematol       Date:  1978-12       Impact factor: 6.998

2.  In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.

Authors:  A Raza; K Ucar; H D Preisler; G Mayers
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

3.  Differentiation of myeloid leukaemic cells: new possibilities for therapy.

Authors:  M Baccarani; S Tura
Journal:  Br J Haematol       Date:  1979-07       Impact factor: 6.998

4.  Response of preleukemic syndromes to continuous infusion of low-dose cytarabine.

Authors:  J S Wisch; J D Griffin; D W Kufe
Journal:  N Engl J Med       Date:  1983-12-29       Impact factor: 91.245

5.  Treatment of leukemia with low-dose ara-C: a study of 160 cases.

Authors:  L Degos; S Castaigne; H Tilly; F Sigaux; M T Daniel
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

6.  Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia.

Authors:  M Baccarani; A Zaccaria; G Bandini; G Cavazzini; R Fanin; S Tura
Journal:  Leuk Res       Date:  1983       Impact factor: 3.156

7.  Effect of ara-A on differentiation and proliferation of HL-60 cells.

Authors:  D Munroe; M Sugiura; J Griffin; D Kufe
Journal:  Leuk Res       Date:  1984       Impact factor: 3.156

8.  The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia.

Authors:  G Browman; J Goldberg; A J Gottlieb; H D Preisler; N Azarnia; R L Priore; J K Brennan; W R Vogler; E F Winton; K B Miller
Journal:  Am J Hematol       Date:  1983-11       Impact factor: 10.047

9.  Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and acute myeloid leukaemia.

Authors:  G E Francis; J E Guimaraes; J J Berney; M A Wing
Journal:  Leuk Res       Date:  1985       Impact factor: 3.156

10.  Low-dose ARA-C fails to enhance differentiation of leukaemic cells.

Authors:  R T Perri; D J Weisdorf; M M Oken
Journal:  Br J Haematol       Date:  1985-04       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.